US Appeals Court Denies Genentech Injunction Over Amgen's 'At Risk' Trastuzumab Launch

 
• By Dave Wallace

Genentech has been denied its request for a US injunction against Amgen over its at-risk launch of a trastuzumab biosimilar rival to Herceptin.

Risk_Scales
After Weighing Genentech’s Arguments, The Court Decided Against An Injunction • Source: Shutterstock

More from Biosimilars

More from Products